đŹ Current Disease Focus:
Task Progress: 0%
đ„ Active Problem Solvers
0
đ Experts collaborating globally
⥠Current Task Assignment
𧏠Genetic Analysis
đ Matching experts to specific tasks
đ Resource Allocation by Research Phase:
đ Data Analysis
đ§Ș Experimental Design
đŹ Clinical Trials
đ Treatment Development
The main aim of the study was to evaluate the real-world tolerability and s...
Status
Completed
Location
Novartis
Start Date
2024-04-24
Trial ID
NCT07148505
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study e...
Status
Recruiting
Location
Ellison Clinic at Saint John's
Start Date
2023-04-17
Trial ID
NCT05768139
The objective of this trial, DBCG R25, will be to evaluate the effect of tr...
Status
Withdrawn
Location
Multiple Locations
Start Date
2026-01-01
Trial ID
NCT06585969
Treatments Being Tested
The purpose of the study is to assess the efficacy and safety of the additi...
Status
Recruiting
Location
Alaska Oncology and Hematology
Start Date
2025-12-22
Trial ID
NCT07174336
Treatments Being Tested
The aim of this study is to assess the clinical adoption, treatment pattern...
Status
Active Not Recruiting
Location
Novartis
Start Date
2026-04-09
Trial ID
NCT07710716
The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4...
Status
Recruiting
Location
Clinique de l'Europe
Start Date
2025-12-18
Trial ID
NCT07237256
Treatments Being Tested
This is an open label, multicenter, single arm phase II study to evaluate t...
Status
Recruiting
Location
University of Alabama at Birmingham
Start Date
2022-09-13
Trial ID
NCT05467891
Treatments Being Tested
This was an open label, multi-center protocol for U.S. patients enrolled in...
Status
Completed
Location
Arizona Oncology Associates PC- HAL
Start Date
2017-06-20
Trial ID
NCT03078751
Treatments Being Tested
The study investigates, whether the patient group with intermediate-risk ea...
Status
Active Not Recruiting
Location
Ost-Alb Klinikum Brustzentrum
Start Date
2019-07-02
Trial ID
NCT04055493
Treatments Being Tested
Hormone receptor (HR)-positive and HER2-negative (HR+/HER2-) metastatic/adv...
Status
Active Not Recruiting
Location
Institut Paoli Calmettes
Start Date
2023-06-20
Trial ID
NCT05529862